HFM
PTGX icon

Hartford Financial Management’s Protagonist Therapeutics PTGX Stock Holding History

Hartford Financial Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300
Closed -$13K – 400
2021
Q2 		$13K Hold
300
– – ﹤0.01% 283
2021
Q1 		$8K Buy
+300
New +$7.59K ﹤0.01% 314

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Hartford Financial Management's PTGX Position: Q3 2021 in Review

Hartford Financial Management sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 300 shares — an estimated $13K sold.

Hartford Financial Management first reported a position in PTGX in Q1 2021 and held it in 2 quarters. The position peaked at $13K in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

  • Hartford Financial Management reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hartford Financial Management sold 300 Protagonist Therapeutics shares in Q3 2021, an estimated $13K.
  • Hartford Financial Management first reported a position in Protagonist Therapeutics in Q1 2021 and held it in 2 quarters.
  • Hartford Financial Management's Protagonist Therapeutics position peaked at $13K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Hartford Financial Management's 13F filing for Q3 2021, filed 29 Oct 2021.